Clinical Nephrology » Etelcalcetide is an innovative drug for the treatment of secondary hyperparathyroidism in patients on programmed hemodialysis (literature review)

Etelcalcetide is an innovative drug for the treatment of secondary hyperparathyroidism in patients on programmed hemodialysis (literature review)

DOI: https://dx.doi.org/10.18565/nephrology.2018.1.74-79

N.A. Mikhailova
FSBEI FPE "Russian Medical Academy of Continuing Professional Education" of RMH, Department of Nephrology and Hemodialysis; Moscow, Russia

The review presents data on the main clinical studies of the efficacy and safety of the new type I calcimimetic in the treatment of secondary hyperparathyroidism, and defines recommendations for its practical application.

Keywords: chronic kidney disease, secondary hyperparathyroidism, calcimimetic, etelcalcetid

Read entire article

About the Autors

Information about the author:
Mikhailova N.A. – PhD in Medical Science, Associate Professor at the Department of Nephrology and Hemodialysis FSBEI FPE RMACPE of RMH; Moscow, Russia.
Е-mail: natmikhailova@mail.ru

Back to Content